Early use of renin–angiotensin–aldosterone system inhibitors and stable renal function in familial focal segmental glomerulosclerosis with ACTN4 mutation: a case report and literature review
Open Access
- 26 September 2025
- journal article
- case report
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-13
Abstract
Background: Genetic mutations in alpha-actinin 4 (ACTN4) are one cause of familial focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (SRNS) in early adulthood, eventually progressing to end-stage kidney disease. Early initiation of renin–angiotensin–aldosterone system inhibitors (RAASis) is reported to delay progression of several forms of familial FSGS and SRNS; however, no cases involving ACTN4 mutations have been reported. Case presentation: A 16-year-old boy was admitted to our hospital for a detailed evaluation of proteinuria that first appeared during treatment for Duchenne muscular dystrophy (DMD) and persisted for 1 year. He had been treated with prednisolone and an angiotensin-converting enzyme inhibitor (ACEi) for 2 years prior to the onset of persistent proteinuria. A renal biopsy revealed segmental sclerosis in 1 of 40 glomeruli, with effaced foot processes observed under electron microscopy. Genetic testing identified ACTN4 mutation (c·776C > T, p.T259I), leading to a diagnosis of autosomal dominant FSGS caused by ACTN4 mutation. After the first appearance of proteinuria, the patient’s renal function and urinary protein levels remained stable for following 7 years. Conclusions: We report a case of adolescent-onset FSGS with ACTN4 mutation diagnosed during ACEi therapy for the prevention of DMD-associated cardiomyopathy. The patient exhibited stable renal function and no disease progression compared with his father and previously reported cases with the same variant. This is the first reported case of early RAASi induction for treating ACTN4-associated FSGS with long-term stable renal function.Keywords
This publication has 81 references indexed in Scilit:
- Non-immunosuppressive treatment for IgA nephropathyCochrane Database of Systematic Reviews, 2024
- Causal and putative pathogenic mutations identified in 39% of children with primary steroid-resistant nephrotic syndrome in South AfricaEuropean Journal of Pediatrics, 2022
- Mutations in INF2 may be associated with renal histology other than focal segmental glomerulosclerosisPediatric Nephrology, 2017
- Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndromePediatric Nephrology, 2015
- Renin–angiotensin–aldosterone system inhibitors in pediatric focal segmental glomerulosclerosisPediatric Nephrology, 2011
- Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin–angiotensin blockade?Pediatric Nephrology, 2009
- α-Actinin structure and regulationCellular and Molecular Life Sciences, 2008
- Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGSPediatric Nephrology, 2007
- The effect of aldosterone blockade in patients with Alport syndromePediatric Nephrology, 2006
- α‐actinin revisited: A fresh look at an old playerCell Motility, 2004